Amgen

Open: 268.52 Close: 269.86 Change: 1.34

The unbelievably easy way to evaluate Amgen Company Inc: Use an AI.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, raise, forecast, fullyear, earnings, share, quarter, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen shares currently sit at $269.86.

Today's News

Amgen agreed to delay launch of its copycat in exchange for J&J dropping a patent infringement lawsuit. Amgen took a $650 million net impairment charge in relation to the axing of AMG 340. Amgen raised its post-acquisition forecast for full-year sales to between $28 billion and $28.4 billion. Excluding a $650 million charge for discontinuing experimental prostate cancer drug AMG340. Amgen is a leader in biotechnology-based human therapeutics. Truist upgraded Amgen (NASDAQ:AMGN) to Buy from Hold with a price target of $320.00 (from $260.00) Amgen raised its post-acquisition forecast for full-year sales to between $28 billion and $28.4 billion. Federal Trade Commission backed down from its contention that Amgen would be able to leverage its big selling drugs to pressure insurance companies to favor Horizons products. Amgen expects full-year earnings in the range of $18.20 to $18.80 per share. Amgen shares have risen slightly since the beginning of the year. Amgen reports third quarter financial results - Barrons. Krystexxa (pegloticase) therapy reduced blood pressure in chronic gout patients. Amgen completes acquisition of Horizon Therapeutics. Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout. Amgen Inc.s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. In 2022, Amgens revenue was $26.32 billion. Amgen completed the $27.8 billion acquisition of Horizon Therapeutics on Friday. The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance. Amgen will present data at the American College of Rheumatologys Annual Meeting across expanded rheumatology pipeline and portfolio. Amgen announced new Phase 3 CodeBreaK 300 results for its KRASG12C inhibitor combination in patients with metastatic colorectal cancer. Amgen to Webcast Investor Call at ESMO 2023 at 8:00 a.m. Amgen Completes $27.8B Horizon acquisition. Amgen Inc. per employee $1.057M P/E ratio 19.19P/E Ratio 19.06Yield 3.16% Dividend $2.13 Ex-Dividend date Nov 16, 2023. Amgen stock has received a consensus rating of hold. The 73 analysts offering price forecasts for Amgen have a median target of 258.36, with a high estimate of 320. Amgen Inc. (AMGN) latest stock news. Shareholder Owner in % Freefloat 99.78 The Vanguard Group, Inc. Amgen shares currently sit at $269.86.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, raise, forecast, fullyear, earnings, share, quarter, and the most common words in the summary are: amgen, bloomberg, inc, news, stock, report, earnings, . One of the sentences in the summary was: Amgen shares currently sit at $269.86.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #bloomberg #inc #news #stock #report #earnings.